3-FA
3-FA is a synthetic substituted amphetamine and fluorinated designer drug that produces potent stimulant effects. It acts as a monoamine releaser reportedly comparable in potency to methamphetamine, though with greater selectivity for dopamine and norepinephrine over serotonin. Part of a series of fluorinated amphetamine analogs that includes 2-FA and 4-FA, it first appeared on the recreational drug market around 2009. It is rarely encountered on the street, primarily circulating as a research chemical through online vendors.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
3-FA produces a potently stimulating experience with a mild entactogenic character that distinguishes it from related fluorinated amphetamines such as 2-FA, 2-FMA, and 4-FA. The experience centers on euphoria, elevated mood, heightened energy, and a strong pull toward socializing and conversation. Unlike 2-FA and 2-FMA, it lacks their reported productivity and focus-enhancing qualities, giving it a more recreational than functional profile.
Physical
The body load is that of a classic stimulant: increased energy and wakefulness alongside appetite suppression, sweating, teeth grinding, itchiness, and disrupted sleep. Weight loss can result from extended or repeated use.
Stimulation
Uncomfortable
Cognitive
The headspace is euphoric, talkative, and socially disinhibited, with a mild entactogenic warmth. It is not well suited to focused work, and irritability, moodiness, and aggressive tendencies can emerge, particularly during the offset or with repeated use.
Emotional
Visual
Visual effects are not a prominent feature of the experience, though hallucinations have been reported.
Auditory
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
3-Fluoroamphetamine has not been individually studied in depth, but available evidence indicates it acts as a substrate-based monoamine releasing agent with selectivity for dopamine and norepinephrine over serotonin, a profile comparable to amphetamine in non-human primate studies. It interacts with the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) to promote monoamine efflux and block reuptake. Like other amphetamine derivatives, it is also expected to displace monoamines from vesicular storage via VMAT2 and to inhibit monoamine oxidase activity, further increasing cytosolic monoamine concentrations.
Pharmacokinetics
The elimination half-life of 3-fluoroamphetamine in rats is approximately 91 minutes, comparable to amphetamine. P450 oxidase metabolism is expected to primarily oxidize the compound at the 4-position. The fluorine substitution at the 3-position enhances blood-brain barrier permeation relative to unsubstituted amphetamine, and the compound's physicochemical properties (small molecular size, low melting point, moderate lipophilicity, and weak basicity with a pKa of 10) are favorable for transdermal absorption.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Dopaminergic stimulants, Entactogens (such as MDMA, due to shared reliance on dopamine and norepinephrine for euphoric effects)
Harm Potential
Addiction & Dependence
Psychological
ModerateLong-term or repeated use may be moderately habit-forming, carries a high risk of abuse, and can lead to psychological dependence in some users. Compulsive redosing is commonly reported, and cravings may develop after regular use is stopped.
Physical
Withdrawal effects may occur if usage is suddenly stopped after dependence develops, though specific physical withdrawal symptoms have not been documented for this substance.
Psychosis Risk
Abuse of amphetamine-class compounds at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Approximately 5-15% of users who develop amphetamine psychosis fail to recover completely, though antipsychotic medications effectively resolve symptoms of acute episodes. Psychosis very rarely arises from therapeutic or occasional use.
History & Culture
3-Fluoroamphetamine emerged as part of a wave of designer fluorinated amphetamine compounds that gained popularity in the late 2000s as research chemical alternatives to traditionally available stimulants. This series includes related compounds such as 2-FA, 2-FMA, 3-FEA, and 4-FA. The substance…
Legality
By Country
References
Source Pages
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-FA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.